

Mosaicism for copy number variations in the placenta is even more difficult to interpret than mosaicism for whole chromosome aneuploidy

Lund, Ida C Bay; Becher, Naja; Graakjaer, Jesper; Lildballe, Dorte L; Uldbjerg, Niels; Bogaard, Pauline; Petersen, Astrid; Vestergaard, Else M; Vogel, Ida

Published in:
Prenatal Diagnosis

DOI (link to publication from Publisher):
[10.1002/pd.5938](https://doi.org/10.1002/pd.5938)

Publication date:
2021

Document Version
Accepted author manuscript, peer reviewed version

[Link to publication from Aalborg University](#)

Citation for published version (APA):

Lund, I. C. B., Becher, N., Graakjaer, J., Lildballe, D. L., Uldbjerg, N., Bogaard, P., Petersen, A., Vestergaard, E. M., & Vogel, I. (2021). Mosaicism for copy number variations in the placenta is even more difficult to interpret than mosaicism for whole chromosome aneuploidy. *Prenatal Diagnosis*, 41(6), 668-680.
<https://doi.org/10.1002/pd.5938>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.


- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.



Connect with experts and peers through Special Interest Groups, a searchable member directory, and interactive events.



Stay informed with online access to *Prenatal Diagnosis* journal, *Global Updates* e-newsletter, and position statements.



Learn through webinars, the International Conference on Prenatal Diagnosis and Therapy, interviews with experts, and recorded talks.

Professional membership is available for medical and allied health professionals.

Trainee membership is complimentary and includes access to Early Career Resources.

Visit www.ispdhome.org for details.



ispd International Society
for Prenatal Diagnosis

Building Global Partnerships in Genetics and Fetal Care



ISPD is a global society of professionals and trainees from disciplines such as prenatal and perinatal care, medical genetics, basic and translational science, genetic counseling, laboratory management, fetal therapy, ultrasonography, and ethics. Become a member today at www.ispdhome.org/join.



www.ispdhome.org info@ispdhome.org +1 434.979.4773

1 Mosaicism for copy number variations in the placenta is even more
2 difficult to interpret than mosaicism for whole chromosome aneuploidy

5 Running title: Placental mosaicism and chromosomal microarray

6 Word count: 3,361

7 Table count: 1

8 Figure count: 3

9 Authors:

10 Ida Charlotte Bay Lund,^{1,2,3} Naja Becher,^{1,2,3} Jesper Graakjaer,⁴ Dorte L. Lildballe,^{2,4} Niels
11 Ulldbjerg,^{5,6} Pauline Bogaard,⁷ Astrid Petersen,⁷ Else Marie Vestergaard,^{1,2,8} Ida Vogel^{1,2,6}

13 Affiliations:

14 ¹Department of Clinical Genetics, Aarhus University Hospital, 8200 Aarhus N, Denmark

15 ²Center for Fetal Diagnostics, Aarhus University Hospital, 8200 Aarhus N, Denmark

16 ³Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark

17 ⁴Clinical Genetics, University Hospital of Southern Denmark, Sygehus Lillebaelt, 7100 Vejle,
18 Denmark

19 ⁵Department of Obstetrics and Gynaecology, Aarhus University Hospital, 8200 Aarhus N, Denmark

20 ⁶Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark

21 ⁷Department of Pathology, Aalborg University Hospital, 9000 Aalborg, Denmark

22 ⁸Present address: Department of Clinical Biochemistry, Horsens Regional Hospital, 8700 Horsens,
23 Denmark

25 Corresponding author:

26 Ida Charlotte Bay Lund

27 Aarhus University Hospital

28 Department of Clinical Genetics

29 Brenstrupgaardsvej 21 C,

30 8200 Aarhus N

31 Denmark

32 Email: idacharlottebaylund@dadlnet.dk

33 Phone: +45 2298 2281

34

26

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/pd.5938](#).

This article is protected by copyright. All rights reserved.

Conflicts of interest: All authors have nothing to declare.

Funding: This work was funded by The Foundation of Aase and Ejnar Danielsen, The Foundation of 17-12-1981 and The Novo Nordisk Foundation. Ida Vogel is funded by a grant from the Novo Nordisk Foundation (NNF16OC0018772).

WHAT'S ALREADY KNOWN ABOUT THIS TOPIC?

- Mosaicism for Copy Number Variations (CNVs) of any size detected in chorionic villus samples (CVSs) may involve the fetus
- CNVs detected by amniocentesis may be discordant to aberrations detected in the postpartum placenta

WHAT DOES THIS STUDY ADDS?

- CVS mosaicism for CNVs may be unreliable in predicting fetal CNVs as such findings may differ from CNVs in the postpartum placenta. Counselling shouldn't focus on the CNV region involved but on the option of amniocentesis.

Data availability statement: Data supporting the findings of this study are available from the corresponding author upon reasonable request.

1

2

Abstract:

Objective: To compare mosaicisms in prenatal chorionic villus samples with corresponding postpartum placental samples.

Method: We collected placentas from 15 consecutive cases of mosaicism detected in chorionic villus samples and obtained five standardized samples on each placenta after delivery. All pre- and postnatal placental samples were uncultured and analyzed by high-resolution chromosomal microarray.

Results: Ten cases of mosaicism for whole chromosome aneuploidy(mWC) and five cases with mosaicism for (sub)chromosomal copy number variations(mCNVs) were included. In 5/10 mWC cases and in 4/5 mCNV cases the prenatally detected aberration was confirmed in the postpartum placenta. Three postpartum placentas revealed various complex aberrations differing from the prenatal results: 1) mosaicisms for different deletions/duplications on 9p and 9q in all samples (prenatal: mosaic 5.3 Mb duplication on 9p24), 2) different regions with deletions/duplications/loss of heterozygosity on 1p in all samples (prenatal: mosaic 2.3 Mb 1p36 duplication), and 3) mosaicism for a duplication on 5q and a deletion on 6p in one out of five samples (prenatal: mosaic trisomy 7).

Conclusion: CNVs constitute a complex subgroup in placental mosaicism. Counseling of these couples after chorionic villus sampling shouldn't focus on the specific CNV involved, but on the nature of mosaicism and the option of amniocentesis and ultrasound.

Keywords: Microarray Analysis < FETAL GENETIC ANALYSIS, Array CGH < PRENATAL CYTOGENETICS, Chorionic villus sampling < FETAL MEDICINE and DIAGNOSTIC PROCEDURES, PRENATAL DIAGNOSIS

25

26

1 INTRODUCTION

2 In prenatal genetics, mosaicism detected after chorionic villus sampling is a recurring clinical
3 challenge as discordance between the placenta and the fetus may exist. Mosaicism is defined as two
4 or more distinct cell lines in the same individual arisen from one zygote¹. Prenatal mosaicism is
5 found in 1-2% of chorionic villus samples after conventional karyotyping of cultured cells and in 1-
6 4% after chromosomal microarray on DNA extracted from uncultured cells²⁻⁷. The majority (80-
7 90%) of these cases are classified as confined placental mosaicism (CPM) without fetal
8 involvement^{2; 6; 8}. Still, true fetal mosaicism (TFM) cannot be ruled out by a normal result on an
9 amniocentesis and the risk of adverse outcome persists. Even without TFM, CPM may cause
10 placental insufficiency leading to intrauterine growth restriction^{9; 10}.

11 Mosaicism in chorionic villus samples has been investigated thoroughly with
12 conventional karyotyping^{2; 7; 11}. However, only a few studies have primarily focused on evaluating
13 mosaicism for Copy Number Variations (CNVs) of any size using chromosomal microarray⁴⁻⁶. The
14 risk of TFM seems equally high in cases of mosaicism for whole chromosome aneuploidy and
15 CNVs of any size, respectively⁶. In pregnancies affected by mosaicism for submicroscopic CNVs
16 confined to the placenta, possible implications for the placental function have only been scarcely
17 investigated^{6; 12}.

18 Previous studies comparing placental mosaicism pre- and postnatally were carried out
19 in the 1980-90 's before the era of high resolution chromosomal microarray^{9; 13-21}. We found no
20 prior data on a consecutive case series of placental mosaicism comparing pre- and postnatal
21 placental sample results using high resolution chromosomal microarray. Such studies are essential
22 to understand and interpret fetoplacental mosaicism for any aberration detected after chorionic
23 villus sampling in pregnancy. We present 15 consecutive cases of placental mosaicism in chorionic
24 villus samples diagnosed by high resolution chromosomal microarray where follow-up with
25 postpartum placental sampling has been performed. We report a new complexity to placental
26 mosaicism with clinical implications related to interpretation of and counselling in cases of
27 placental mosaicism.

28

29

30

31

1

2 **METHODS**

3 In the Danish prenatal screening program ~96% of all women participate in a combined 1st
 4 trimester screening. If further testing is indicated a total of 80% of women choose invasive testing
 5 over Non-Invasive Prenatal Testing and chorionic villus sampling is the more commonly used
 6 invasive method ^{22; 23}. According to the national prenatal guidelines, chromosomal microarray is
 7 applied on all chorionic villus samples regardless of indication ^{24; 25}. In our local Clinical Genetics
 8 Service, we receive approximately 600 chorionic villus samples annually and mosaicism is detected
 9 in overall ~4%.⁶

10 Ethical approval for the study was obtained by The Central Denmark Region
 11 Committee on Health Research Ethics (1-10-72-188-17). Pregnant women were consecutively
 12 recruited from the department of clinical genetics in Central Denmark Region from May 2017 to
 13 August 2018 if a transabdominal chorionic villus sampling had been performed and mosaicism for
 14 any aberration had been detected using chromosomal microarray. After approval from The Regional
 15 Research Ethics Committee Central Denmark Region (October 2017) we recruited pregnant women
 16 prospectively but we also searched our internal laboratory database for prenatal mosaic results to
 17 identify pregnant women who had received a mosaic result after CVS before October 2017 to boost
 18 the sample size. We included cases consecutively according to Supplementary Figure S1. When
 19 eligible participants had given consent to join the study the medical record were updated with
 20 information to the midwives to store the placenta after birth. On the consent form, participants
 21 could also permit data from the medical record to be used for the study. Abnormal outcome was
 22 defined as TFM, intrauterine death, stillbirth, preterm birth, intrauterine growth restriction or small-
 23 for-gestational-age infants (birth weight <-2SD).

24 From this point onwards, the abbreviation “CVS” is used for a chorionic villus sample
 25 obtained by chorionic villus sampling in pregnancy and “ppCVS” is used for a chorionic villus
 26 sample obtained by sampling the *postpartum* placenta.

27 Local standard procedures for prenatal chromosomal microarray on CVSs were
 28 followed in all cases. Briefly, DNA from 10-20mg uncultured and untrypsinized CVS was analyzed
 29 with array-based Comparative Genomic Hybridization, aCGH (Sureprint G3 Human CGH
 30 microarray 180 K/ Agilent Technologies Inc., Santa Clara, CA, USA). CytoGenomics version
 31 3.0.6.6 was used for data analysis. An average log2 ratio below the expected 0.585 for duplications
 32 and above -1.0 for deletions were evaluated for mosaicism. The level of mosaicism (frequency of

abnormal cells) (%) was determined based on the specific value of the log2 ratio by an experienced laboratory geneticist. The prenatally detected mosaic cases were categorized into two main groups: 1) mosaicism for whole chromosome aneuploidy, autosomal or sex chromosomal trisomies or sex chromosomal monosomy – as whole chromosome mosaicism (mWC) and 2) mosaicism for CNVs defined as any partial chromosome or submicroscopic aberration – as CNV mosaicism (mCNV).

Postpartum placentas were stored for a maximum of three days at +5°C or frozen at -18°C. Five ppCVSs were obtained from the fetal surface according to a standardized method where each ppCVS in all placentas was performed exactly the same way. The ppCVSs were obtained 1/3 radially from the placental margin at four quadrantal positions, clockwise, 12 (ppCVS_A), 3 (ppCVS_B), 6 (ppCVS_C) and 9 (ppCVS_D), and one in the middle (ppCVS_E) (Figure 1). Between each ppCVS new sterile instruments were used to avoid inter-sample contamination. The ppCVSs were stored at -80°C until dissection into 10 mg samples. The dissected samples were then washed in phosphate-buffered saline and treated with Proteinase K. DNA was isolated using the Matwell kit rack (Maxwell®16 MDx, Promega) and kept at -80 C until analyses. SNP arrays (Illumina CytoSNP-12 Single-Nucleotide-Polymorphism (SNP) -array; working resolution 50 kb) was applied on ppCVSs. DNA from the corresponding CVS was reanalyzed by SNP array for comparability as they were analyzed in the prenatal setting by aCGH. Genotypes in CVS and ppCVS from the same pregnancy were compared to rule out 100% maternal cell contamination in cases of normal female 46,XX. Genome Studio's Heritability test was performed to check for sample switch and reduced data quality. KaryoStudio analysis software and BluefuseMulti were used for data analysis. Level of mosaicism was visually interpreted and estimated based on B-allele frequency according to Conlin et al.²⁶. Results from each ppCVS were categorized as *fully concordant* (identical to the mosaicism detected in CVS, but the level of abnormal cell line was allowed to vary), *related concordant* (mosaicism at the same chromosome/chromosomal region as detected in CVS), *discordant abnormal* (mosaicism of a different chromosome than the mosaicism detected in CVS) or *normal* (normal non-mosaic molecular karyotype). These categories have been modified from Zhu et al.²⁷.

Study data were collected and managed using REDCap electronic data capture tools hosted at Aarhus University, Denmark. For statistical analysis we used Stata v.16. The Fisher's exact test was used for comparison of proportions. The Danish Data Protection Agency approved the study (1-16-02-659-16). Six prenatal cases from the present study have been published

1 previously but postnatal results from postpartum placental samples were not included in this
2 previous publication⁶.

4 RESULTS

5 3.1 Overall comparison of pre- and post-natal chorionic villus samples

6 The 15 mosaic CVS results included ten cases of whole chromosome aneuploidy (mWC) and five
7 cases with partial (sub)chromosomal aberrations (mCNV), Table 1. When we compared results
8 from the ppCVSs and the prenatally obtained CVS, data were heterogenous. Individual results from
9 each case are visually presented in Figure 1. SNP array plots of all aberrations are included in
10 Supplementary Figure S2.

11 Regarding the ten cases of mWC, the exact aberration detected in the CVS was
12 confirmed in the postpartum placenta in five cases (*fully concordant*) and not confirmed in five
13 cases (*normal or discordant abnormal*). One complex case with mosaicism for trisomy 7 in CVS
14 (case 9), revealed different CNVs in one ppCVS; these CNVs had not been detected in the CVS
15 (*discordant abnormal*).

16 Regarding the five cases with mCNV in the CVS, the aberration detected in the CVS
17 was concordant (*fully or related concordant*) in four of the postpartum placentas. The aberrations
18 detected in two of these placentas (cases 11 and 13) were, however, complex showing variation in
19 near proximity to the region affected in the CVS (*related concordant*). In 1/5 of the mCNV-cases,
20 no aberrations were found in the postpartum placentas (*normal*).

21 The probability of confirming mosaicism in the postpartum placenta was high in the
22 CVSs with levels of mosaicism $\geq 30\%$ (n=7) compared with the CVSs with a level of mosaicism
23 $< 30\%$ (n=8) (7/7, 100% vs 2/8, 25%, $p=0.007$). In general, when comparing levels of mosaicism
24 between the CVS and the fully concordant ppCVSs within each case, differences were within a
25 range of +/- 20%.

27 3.2 Complex results

28 Altogether, we had 3/15 particularly complex cases (cases 9, 11, 13) – all
29 demonstrating mosaicisms for different CNVs in the postpartum placenta, which were not detected
30 prenatally in the CVS. In these three placentas, the complex results between CVS and ppCVSs

could be categorized in *related concordant* (cases 11 and 13) or *discordant abnormal* (cases 11 and 9). All three cases had normal results on follow-up amniocentesis (aCGH) indicating CPM.

Figure 2 explains cases 11, 13 and 9 in detail and actual SNP array plots are included in Figure 3 and Supplementary Figure S2.

- Case 11:

The CVS showed a mosaic 5.3 Mb 9p24 duplication. Postnatally, this specific duplication was not confirmed in any of the ppCVSs; instead, quite different aberrations located to 9p were detected in all five postpartum samples. These aberrations on 9p in the ppCVSs included mosaicism of deletions and duplications of various sizes and more than one aberration in the same ppCVS. All ppCVS_A-E results were different and ppCVS_E included additional aberrations on 9q. Furthermore, a mosaic 6.9 Mb duplication on chromosome 20p was detected in ppCVS_C.

- Case 13:

The CVS showed a mosaic 2.3 Mb 1p36 duplication which was confirmed (*fully concordant*) in a mosaic state in ppCVS_E. The other four ppCVSs_A-D showed different aberrations on 1p; mosaicism of a deletion (ppCVS_A) and regions with loss of heterozygosity including a duplication (ppCVS_B-D).

- Case 9:

Mosaicism for trisomy 7 was detected in the CVS but not confirmed in any of the ppCVSs (data not shown). Instead three aberrations, not detected in the CVS, were detected in ppCVS_D; mosaic 20 Mb duplication on 5q34, mosaic 7.2 Mb deletion on 6p25 and non-mosaic 762 Kb duplication on 8q23.

None of these three complex cases revealed, in any of the samples, a third haplotype in the B-allele frequency, indicating a Meiosis I error, in the SNP array results.

3.3 Clinical outcome

Overall, 5/15 pregnancies (33%, CI95%:13-61%) had an abnormal pregnancy outcome. Two pregnancies were classified as TFM by fetal buccal swab (case 1) or postnatal blood sampling (case 4). Three pregnancies affected by CPM had an adverse outcome (intrauterine death in case 10, intrauterine growth restriction in case 9 and small-for-gestational-age infant in case 6). The remaining ten pregnancies classified as CPM were uneventful and resulted in live born,

1 phenotypically normal infants.

2 Based on the results from three complex CPM cases (9, 11 and 13), where the
3 ppCVSs were related concordantly or/and discordantly abnormal to the corresponding CVSs, we
4 suggest a new sub-category of CPM termed *complex* CPM (Supplementary Figure S3).

5

6 **DISCUSSION**

7 In this study, we identify a new complexity to the field of placental mosaicism and
8 show that mosaicism for CNVs detected prenatally by CMA can be accompanied by multiple
9 aberrations, in the postpartum placenta such as deletions, duplications or/and loss of heterozygosity
10 of varying size. This new knowledge is of outmost importance for clinical geneticists and fetal
11 medicine experts and makes the interpretation of results, and the counseling of these patients, even
12 more challenging. Adverse outcomes, such as TFM or CPM with stillbirth, intrauterine growth
13 restriction or small-for-gestational-age infant, were overall frequent and found in 5/15 (33%,
14 CI95%:13-61%) pregnancies although not among the five pregnancies with CPM for CNVs.

15 Placental whole chromosome mosaicism detected in a CVS, including evidence for
16 the persistence of mosaicism to term, is reported in the literature based on conventional karyotyping
17 and low-resolution chromosomal microarray^{9; 13-21}. These previous studies have documented that
18 mosaicism for whole chromosome aneuploidy or structural rearrangements detected in CVS have
19 stable cell lines; either the normal disomic and/or abnormal trisomic/monosomic/structural cell line
20 detected is correspondingly detected in the postpartum placenta^{9; 14-20}. This is in line with 9/10
21 cases of mosaic whole chromosome aneuploidy in our study where no other aberrations were
22 detected in the postpartum placenta. We also found the same correlation as Kalousek et al.⁹; a level
23 of mosaicism ≥ 30 -35% in the CVS will increase the likelihood of confirmation in at least one
24 postpartum placental sample. It may thus be suggested that the level of mosaicism in the CVS is
25 correlated to the distribution of abnormal cell line(s) in the placenta.

26 The present case series highlights at least two important new findings in the
27 postpartum placenta as compared to prenatal CVS; 1) complex variation in the near proximity to the
28 chromosomal region affected in the CVS and 2) other aberrations including entirely different
29 chromosomes. Such discrepancies between a mosaic CNV in a CVS and a mosaic CNV in the
30 concordant postpartum placenta have, to our knowledge, not been reported before. This finding may
31 potentially change the way we handle similar cases in the future – both in clinical genetics and in

1 fetal medicine.

2 Opstal *et al.* investigated postpartum placentas from pregnancies with discrepant
3 results between Non-Invasive Prenatal Testing and CMA on amniotic fluid but they did not
4 investigate CVSs²⁸. Similarly, though, they detected different aberrations in the postpartum
5 placenta not detected in the amniotic fluid. In the current study, two cases (11 and 13) were
6 categorized in *related concordance* because different mosaic CNVs in the same chromosomal
7 region as in the CVS were detected postpartum. Since both pregnancies had normal CMA result on
8 the follow-up sample of uncultured amniocytes, the mCNV would likely be confined to the
9 placenta. The most likely explanation for the confinement of these CNVs to the placenta is that
10 these CNVs have originated due to mitotic errors during placental development. A single meiotic
11 origin of these aberrations seems less likely because the CNVs could not be confirmed in the fetus.
12 This hypothesis is supported by the B-allele frequency not displaying a third haplotype in any of the
13 samples; although a Meiosis II error could not be excluded. Repair mechanisms in the following
14 cell divisions may explain the occurrence of different CNVs or loss of heterozygosity in a specific
15 chromosomal region. In the literature, a commonly accepted explanation of the mechanisms behind
16 the origin of CNVs (mosaic or non-mosaic) has no definite evidence²⁹⁻³¹. All three cases with
17 mosaicism for smaller CNVs (<6 Mb) in CVS had *full* (case 7, 7q11 duplication) or *related*
18 *mosaicism* (cases 11 and 13) distributed in all their individual ppCVSs. It could be speculated that
19 there may be less selection pressure against smaller CNVs compared to mosaicism for an entire
20 chromosome. Further investigations are needed before hypotheses can be generated for the
21 mechanisms behind discrepancies involving the *same chromosome* in prenatal CVS and the
22 corresponding ppCVSs.

23 The discovery of new aberrations involving entirely different chromosomes in the
24 postpartum placenta, compared to the involved chromosome in the CVS, occurred in two cases (9
25 and 11). One explanation may be the nature of placental growth, which has been compared to tumor
26 growth because it is invasive with a high mitotic index^{32; 33}. Three of the “new” CNVs detected in
27 the postpartum placental samples were large (20, 7.2 and 6.9 Mb respectively, Figure 2), and would
28 likely be detectable by conventional karyotyping. The reason why such findings have not been
29 reported before in postpartum placental studies using conventional karyotyping may be due to
30 selection bias against cell lines with large CNVs during culturing. This would likely, if detected in
31 one metaphase alone, have been interpreted as pseudomosaicism and disregarded¹³. Opstahl *et al.*²⁸
32 have detected mosaicism for a microscopic CNV with CMA, not detected by NIPT nor AC sample,

1 in one postpartum placental sample in one case. We saw this phenomenon of “new” CNVs not
 2 related to CVS results in only two postpartum placental samples. Thus, microscopically sized CNVs
 3 appear at specific placental sites and may be a rare event compared to an extensive load of small
 4 CNVs (<2Mb) detected in postpartum placentas in accordance with Kasak *et al.*³². It is possible,
 5 therefore, that CNVs of any size in the placenta may be missed in a CVS or CNVs which seem to
 6 have no clinical significance may be detected in a CVS. We do not know, however, if these CNVs
 7 develop over time (“in vivo culture” of the placenta) or if they are present at the gestational age
 8 where the chorionic villus sample is obtained. In the future, if resolution of Non-Invasive Prenatal
 9 Testing improves this subject can be further explored as cell-free placental DNA in maternal blood
 10 is believed to represent the entire trophoblastic layer of the placenta and not just a single site as a
 11 CVS³⁴.

12 Based on the findings discussed above, we suggest that it is redundant to complete a
 13 detailed evaluation when CNVs are detected in a mosaic state in uncultured cells from CVS by
 14 chromosomal microarray as other parts of the placenta, and potentially the fetus, may contain
 15 diverse but clinical significant CNVs. Counselling of couples after a diagnosis of mosaic CNV in a
 16 CVS is challenging and we may not need to focus on the specific chromosomal region involved.
 17 Instead, efforts should be put into understanding and explaining the nature of mosaicism and
 18 prepare the couple to cope with the long waiting time related to further investigations of these
 19 findings. If the couple wants to know more about the risk of TFM, amniocentesis should be offered.
 20 Fetal ultrasonography detecting malformations and growth retardation may be the modality to
 21 manage these cases until more knowledge regarding the mechanisms and clinical consequences of
 22 placental CNV mosaicism is obtained.

23 The possible implications of mosaic CNVs in the placenta on placental function need
 24 to be investigated further as our case-series is small. Outcomes in pregnancies affected by CPM for
 25 whole chromosome aneuploidy vary depending on the chromosome involved and the level and
 26 distribution of mosaicism³⁵. We found no association between obstetric outcome and distribution
 27 of mosaic cell lines in the postpartum placenta. Contrary, Robinson *et al.* evaluated the frequency of
 28 trisomic cells by CGH (resolution >10 Mb) in postpartum placentas ascertained by intrauterine
 29 growth restriction and observed trisomic cell lines in 10%³⁶. Likewise, pregnancies with abnormal
 30 outcome and normal (or no) CVS results could be due to placental mosaicism absent from the
 31 sampling site of the CVS; our results indicate that this may be a potential scenario. Postpartum
 32 placental studies with high resolution chromosomal microarray may be a supplement to placental

1 pathology examination in pregnancies of severe intrauterine growth restriction or fetal death, if fetal
2 investigations do not provide an explanation.

3 One limitation of this study is that culturing of the pre- and postnatal samples was not
4 performed. Therefore, we could not supplement our results with conventional karyotyping or FISH,
5 but next generation cytogenetics after whole genome sequencing could be applied for a better
6 understanding of the somatic chromosomal variation in the placenta in future studies investigating
7 uncultured samples. Furthermore, we cannot discuss whether the mosaicism was detected in
8 cytotrophoblasts or in mesenchymal cells but there is always a risk of TFM regardless of which
9 chorionic villi layer is affected by an abnormal cell line².

11 CONCLUSION

12 Mosaicism for CNVs detected in uncultured CVSs constitute a complex subgroup and
13 seems unreliable for the prediction of fetal phenotype and placental function. Regardless of affected
14 CNV region in mosaic state, these results should be followed by amniocentesis and detailed fetal
15 ultrasonography if the couple wants to know more about the risk of TFM. Repair mechanisms after
16 prenatal de novo CNVs are evident and need further exploration to understand the nature of the
17 placenta in more detail. Data on amniocentesis, fetal/newborn tissue and long-term follow-up of
18 live born infants should be systematically collected for a large international cohort of cases of
19 mosaicism. Such data could be used to increase knowledge in this field making also mosaic results
20 in a CVS contribute with reliable and useful information. This may also provide new insight into
21 unknown repair mechanisms of CNVs.

1

2 References

- 3 1. Kalousek, D.K. (2000). Pathogenesis of chromosomal mosaicism and its effect on early human
4 development. *Am J Med Genet* 91, 39-45.
- 5 2. Grati, F.R., Malvestiti, F., Branca, L., Agrati, C., Maggi, F., and Simoni, G. (2017). Chromosomal mosaicism
6 in the fetoplacental unit. *Best practice & researchClinical obstetrics & gynaecology* 42, 39-52.
- 7 3. Firth, H., and Hurst, J. (2005). chapter V, chromosomal mosaicism- prenatal. In *Oxford desk reference:*
8 *Clinical genetics* (New York, Oxford), p 516.
- 9 4. Gu, S. (2018). Chromosomal microarray analysis on uncultured chorionic villus sampling can be
10 complicated by confined placental mosaicism for aneuploidy and microdeletions. *Prenatal diagnosis*
11 38, 858-865.
- 12 5. Carey, L. (2014). Prenatal diagnosis of chromosomal mosaicism in over 1600 cases using array
13 comparative genomic hybridization as a first line test. *Prenatal diagnosis* 34, 478-486.
- 14 6. Lund, I.C.B., Becher, N., Christensen, R., Petersen, O.B., Steffensen, E.H., Vestergaard, E.M., and Vogel, I.
15 (2020). Prevalence of mosaicism in uncultured chorionic villus samples after chromosomal
16 microarray and clinical outcome in pregnancies affected by confined placental mosaicism. *Prenat*
17 *Diagn* 40, 244-259.
- 18 7. Battaglia, P. (2014). Cytogenetic follow-up of chromosomal mosaicism detected in first-trimester
19 prenatal diagnosis. *Prenatal diagnosis* 34, 739-747.
- 20 8. Malvestiti, F., Agrati, C., Grimi, B., Pompilli, E., Izzi, C., Martinoni, L., Gaetani, E., Liuti, M.R., Trotta, A.,
21 Maggi, F., et al. (2015). Interpreting mosaicism in chorionic villi: results of a monocentric series of
22 1001 mosaics in chorionic villi with follow-up amniocentesis. *Prenatal diagnosis* 35, 1117-1127.
- 23 9. Kalousek, D.K., Howard-Peebles, P.N., Olson, S.B., Barrett, I.J., Dorfmann, A., Black, S.H., Schulman, J.D.,
24 and Wilson, R.D. (1991). Confirmation of CVS mosaicism in term placentae and high frequency of
25 intrauterine growth retardation association with confined placental mosaicism. *Prenat Diagn* 11,
26 743-750.
- 27 10. Wilkins-Haug, L., Quade, B., and Morton, C.C. (2006). Confined placental mosaicism as a risk factor
28 among newborns with fetal growth restriction. *Prenatal diagnosis* 26, 428-432.
- 29 11. Hahnemann, J.M., and Vejerslev, L.O. (1997). European collaborative research on mosaicism in CVS
30 (EUCROMIC)--fetal and extrafetal cell lineages in 192 gestations with CVS mosaicism involving single
31 autosomal trisomy. *American Journal of Medical Genetics* 70, 179-187.
- 32 12. Eckmann-Scholz, C., Mallek, J., von Kaisenberg, C.S., Arnold, N.K., Jonat, W., Reiner, S., Caliebe, A., and
33 Heidemann, S. (2012). Chromosomal mosaicisms in prenatal diagnosis: correlation with first
34 trimester screening and clinical outcome. *Journal of perinatal medicine* 40, 215-223.
- 35 13. Kalousek, D.K., and Dill, F.J. (1983). Chromosomal mosaicism confined to the placenta in human
36 conceptions. *Science* 221, 665-667.
- 37 14. Kalousek, D.K., Dill, F.J., Pantzar, T., McGillivray, B.C., Yong, S.L., and Wilson, R.D. (1987). Confined
38 chorionic mosaicism in prenatal diagnosis. *Human genetics* 77, 163-167.
- 39 15. Callen, D.F., Korban, G., Dawson, G., Gugasyan, L., Krumins, E.J., Eichenbaum, S., Petrass, J., Purvis-
40 Smith, S., Smith, A., Den Dulk, G., et al. (1988). Extra embryonic/fetal karyotypic discordance during
41 diagnostic chorionic villus sampling. *Prenat Diagn* 8, 453-460.
- 42 16. Schwinger, E., Seidl, E., Klink, F., and Rehder, H. (1989). Chromosome mosaicism of the placenta--a
43 cause of developmental failure of the fetus? *Prenat Diagn* 9, 639-647.
- 44 17. Miny, P., Hammer, P., Gerlach, B., Tercanli, S., Horst, J., Holzgreve, W., and Eiben, B. (1991). Mosaicism
45 and accuracy of prenatal cytogenetic diagnoses after chorionic villus sampling and placental
46 biopsies. *Prenat Diagn* 11, 581-589.
- 47 18. May, K.M., Saxe, D.F., and Priest, J.H. (1992). Confirmation of CVS mosaicism. *Prenat Diagn* 12, 626-627.

- 1 19. Schuring-Blom, G.H., Keijzer, M., Jakobs, M.E., Van den Brande, D.M., Visser, H.M., Wiegant, J., Hoovers,
2 J.M., and Leschot, N.J. (1993). Molecular cytogenetic analysis of term placentae suspected of
3 mosaicism using fluorescence in situ hybridization. *Prenatal diagnosis* 13, 671-679.
- 4 20. Henderson, K.G., Shaw, T.E., Barrett, I.J., Telenius, A.H., Wilson, R.D., and Kalousek, D.K. (1996).
5 Distribution of mosaicism in human placentae. *Human genetics* 97, 650-654.
- 6 21. Lestou, V.S., Lomax, B.L., Barrett, I.J., and Kalousek, D.K. (1999). Screening of human placentas for
7 chromosomal mosaicism using comparative genomic hybridization. *Teratology* 59, 325-330.
- 8 22. Lou, S., Petersen, O.B., Jorgensen, F.S., Lund, I.C.B., Kjaergaard, S., Danish Cytogenetic Central Registry
9 Study, G., and Vogel, I. (2018). National screening guidelines and developments in prenatal
10 diagnoses and live births of Down syndrome in 1973-2016 in Denmark. *Acta Obstetrica et*
11 *Gynecologica Scandinavica* 97, 195-203.
- 12 23. Lund, I.C.B., Petersen, O.B., Becher, N.H., Lildballe, D.L., Jørgensen, F.S., Ambye, L., Skibsted, L., Ernst,
13 A., Jensen, A.N., Fagerberg, C., et al. (2020). National data on the early clinical use of non-invasive
14 prenatal testing in public and private healthcare in Denmark 2013-2017. *Acta Obstet Gynecol*
15 *Scand.* DOI: 10.1111/aogs.14052
- 16 24. Vogel, I., Petersen, O.B., Christensen, R., Hyett, J., Lou, S., and Vestergaard, E.M. (2017). Chromosomal
17 microarray as a primary diagnostic genomic tool for pregnancies defined as being at increased risk
18 within a population based combined first-trimester screening program. *Ultrasound in obstetrics &*
19 *gynecology : the official journal of the International Society of Ultrasound in Obstetrics and*
20 *Gynecology*.
- 21 25. National Prenatal Guidelines in Denmark. In., pp [https://www.sst.dk/da/viden/graviditet-og-](https://www.sst.dk/da/viden/graviditet-og-foedsel/svangreomsorgen/fosterdiagnostik)
22 [foedsel/svangreomsorgen/fosterdiagnostik](https://www.sst.dk/da/viden/graviditet-og-foedsel/svangreomsorgen/fosterdiagnostik).
- 23 26. Conlin, L.K., Thiel, B.D., Bonnemann, C.G., Medne, L., Ernst, L.M., Zackai, E.H., Deardorff, M.A., Krantz,
24 I.D., Hakonarson, H., and Spinner, N.B. (2010). Mechanisms of mosaicism, chimerism and
25 uniparental disomy identified by single nucleotide polymorphism array analysis. *Human molecular*
26 *genetics* 19, 1263-1275.
- 27 27. Zhu, X., Chen, M., Wang, H., Guo, Y., Chau, M.H.K., Yan, H., Cao, Y., Kwok, Y.K.Y., Chen, J., Hui, A.S.Y., et
28 al. (2020). Clinical utility of expanded noninvasive prenatal screening and chromosomal microarray
29 analysis in high risk pregnancies. *Ultrasound Obstet Gynecol*.
- 30 28. Van Opstal, D., van Veen, S., Joosten, M., Diderich, K.E.M., Govaerts, L.C.P., Polak, J., van Koetsveld, N.,
31 Boter, M., Go, A., Papatsonis, D.N.M., et al. (2019). Placental studies elucidate discrepancies
32 between NIPT showing a structural chromosome aberration and a differently abnormal fetal
33 karyotype. *Prenat Diagn* 39, 1016-1025.
- 34 29. Matsubara, K., Yanagida, K., Nagai, T., Kagami, M., and Fukami, M. (2020). De Novo Small
35 Supernumerary Marker Chromosomes Arising From Partial Trisomy Rescue. *Frontiers in genetics*
36 11, 132.
- 37 30. Kurtas, N.E., Xumerle, L., Leonardelli, L., Delledonne, M., Brusco, A., Chrzanowska, K., Schinzel, A.,
38 Larizza, D., Guerneri, S., Natacci, F., et al. (2019). Small supernumerary marker chromosomes: A
39 legacy of trisomy rescue? *Hum Mutat* 40, 193-200.
- 40 31. Dos Santos, A., Campagnari, F., Krepischi, A.C.V., Ribeiro Câmara, M.L., de Arruda Brasil, R.C.E., Vieira,
41 L., Vianna-Morgante, A.M., Otto, P.A., Pearson, P.L., and Rosenberg, C. (2018). Insight into the
42 mechanisms and consequences of recurrent telomere capture associated with a sub-telomeric
43 deletion. *Chromosome research : an international journal on the molecular, supramolecular and*
44 *evolutionary aspects of chromosome biology* 26, 191-198.
- 45 32. Kasak, L., Rull, K., Vaas, P., Teesalu, P., and Laan, M. (2015). Extensive load of somatic CNVs in the
46 human placenta. *Scientific reports* 5, 8342.
- 47 33. Tedde, G., and Tedde Piras, A. (1978). Mitotic index of the Langhans' cells in the normal human placenta
48 from the early stages of pregnancy to the term. *Acta anatomica* 100, 114-119.
- 49 34. Brison, N. (2018). Predicting fetoplacental chromosomal mosaicism during non-invasive prenatal
50 testing. *Prenatal diagnosis* 38, 258-266.

- 1 35. Kalousek, D.K., and Vekemans, M. (1996). Confined placental mosaicism. *Journal of medical genetics* 33,
2 529-533.
- 3 36. Robinson, W.P., Peñaherrera, M.S., Jiang, R., Avila, L., Sloan, J., McFadden, D.E., Langlois, S., and von
4 Dadelszen, P. (2010). Assessing the role of placental trisomy in preeclampsia and intrauterine
5 growth restriction. *Prenat Diagn* 30, 1-8.
- 6

Table 1. Prenatal chorionic villus sample results and clinical characteristics from the 15 included cases.

Type of mosaicism	Given case nb	Aberration in CVS sample by CMA during pregnancy	1. trimester characteristics					Birth characteristics				Placental characteristics		
			Indication (GA at CVS)	MA (y)	PaPP-A (MoM)	β-hCG (MoM)	NT mm	Outcome	GA at birth	BW (g)	BW (z-score)	PW g (percentile)	Diameter mm (range)	Sample W median mg (range)
Common aneuploidy, n=3														
	1	T21	NT> 3.5 mm (12+5)	27	0.482	0.465	3.8	TOP	14+4	na	na	na	55-90	197 (100;281)
	2	T13	cFTS> 1:100 (13+2)	35	0.548	0.980	2.6	LB	39+6	4175	1.3	634 (>90th)	210-220	288 (232;499)
	3	T13	TR (FHR: 130) (13+3)	34	0.675	1.064	2.1	LB	40+1	4370	1.6	570 (50th)	170-190	371 (336;492)
Sex chromosomal aberrations, n=2														
	4	X (XX)	Family history (10+4)	35	0.445	2.349	1.4	LB	40+5	3540	-0.2	457 (~10th)	170-195	185 (135;247)
	5	X(XX)	cFTS> 1:300 (13+3)	32	0.472	2.938	2.0	LB	41+5	3760	-0.1	na	160-180	224 (164;355)
Other whole chromosome aneuploidy, n=5														
	6	T7	cFTS> 1:100 (13+1)	32	0.212	0.901	1.5	LB	38+6	2855	-2.2	368 (<10 th)	140-150	223 (135;296)
	7	T3/T7/T15	Family history and cFTS 1:700-1:300 (12+6)	43	7.089	1.968	2.0	LB	38+1	4265	2.6	790 (>90th [†])	na	na
	8	T11	NT> 3.5 mm (13+4)	44	2.499	0.999	3.9	LB	41+3	3140	-1.6	419 (<10th)	na	na
	9	T7	Family history (13+1)	37	0.476	0.705	2.8	LB	37+2	2100	-2.5	340 (<10th [‡])	na	na
	10	T7	cFTS> 1:300	30	0.657	0.521	3.0	IUD [§]	36+3	3180	0.8	646 (>90 th)	na	na

			(14+2)											
CNV/partial chromosome aberration, n=5														
	11	9p24.1p23 dup (5.3 Mb)	cFTS> 1:300 (11+6)	36	0.316	0.362	1.2	LB	40+1	3590	-0.2	740 (na [†])	170-200	448 (277;533)
	12	T18p or tetrasomy 18p	cFTS> 1:300 (13+0)	37	0.267	0.232	0.8	LB	40+0	3000	-1.5	355 (<10 th)	165-180	361 (301;481)
	13	1p36.33 p36.32 dup (2.3 Mb)	PaPP-A<0.2 MoM (13+2)	28	0.199	0.399	2.5	LB	38+0	2498	-1.9	335 (<10 th)	140-145	273 (172;403)
	14	7q11.21 dup (1.5 Mb)	cFTS> 1:100 (13+1)	32	0.401	1.654	2.3	LB	40+4	3328	-0.7	540 (na [†])	170-180	275 (208;334)
	15	8q13.2q24.3 dup (75 Mb)	NT≥ 3.5 mm (14+0)	31	1.090	0.864	3.5	LB	39+4	3706	0.6	640 (na [†])	190-190	na

[†] Placenta weighed fresh

[‡] Maternal antithrombin deficiency and previous child with intrauterine growth restriction

[§] Significant heart malformation detected at gestational week 29. IUD in gestational week 36.

Placentas were either stored cold (n=10; maximum of three days) or frozen at -20C (n=3; maximum of 13 days). Two placentas were accidentally fixed in formalin (case 8 and 10) before samples. Macro- and microscopically pathology examination of placentas did not reveal any certain characteristics for mosaicism except in case 10 where oedema of larger villi was found; this finding could be due to mosaicism but also fetal hydrops.

Abbreviations: β -hCG, free β human chorion gonadotropin; BW, birth weight; cFTS, combined first trimester screening; CMA, chromosomal microarray; CVS, chorionic villus sampling; ; dup, duplication; FHR, fetal heart rate; GA, gestational age; IUD, intrauterine death; LB, liveborn and apparently healthy at birth; MA, maternal age; MoM, multiple of the median; na, none available; NT, nuchal translucency measurement; PaPP-A, pregnancy associated protein A; pp, postpartum placental; PW, placenta weight, TOP, termination of pregnancy; TR, tricuspid regurgitation.

Figure Legend

Figure 1. Results from postpartum chorionic villus samples in 15 placentas.

The fetal site of the postpartum placenta is shown for all 15 cases. Each postpartum chorionic villus sample is marked by a circle.

FIGURE 2 Legend

Figure 2. Three placentas with complex results

The figure shows four complex results from three placentas: Case 11 (2A and 2C), Case 13 (2B) and Case 9 (2D). In Figure 2A, 2B and 2C the six bars display the results from the prenatal chorionic villus sample (CVS) and the five postpartum chorionic villus samples (ppCVS_A-E). In Figure 2D, three bars show results from a single ppCVS_D and three bars show joined normal results from CVS and ppCVS_A-C,E. Deletions are coloured in red and duplications are coloured in blue. The intensity of the colours matches the level of mosaicism. Loss of heterozygosity (LOH) is coloured in yellow. SNP plots can be found in Figure 3 and Supplementary Figure S2.

2A:

Results from chromosome 9 of Case 11 are shown.

CVS: 5.3 Mb dup, arr[GRCh]9p24.1p23(8065133-13415908)x~2-3 (Level mos 55-60/60%)

ppCVS_A: 16.3 Mb del, (arr[GRCh37]9p24.3p22.2(1019207- 17340864) x~1-2 (Level mos 75-80%) and a 4.2 Mb dup, (arr[GRCh37]9p22.2-21.3(17720175- 21920346) x~2-3) (Level mos 70-80%)

ppCVS_B: Non-mosaic 285 Kb dup (arr[GRCh37]9p24.3(46587-331490)x3)

ppCVS_C: 6.4 Mb del, (arr[GRCh37]9p24.3-24.1(1501977-7902733) x~1-2) (Level mos 80%) and a 1.1 Mb dup (arr[GRCh37]9p24.1-p23(7,945,146-9,064,330) x~2-3) (Level mos 50%)

ppCVS_D: 9.8 Mb dup (arr[GRCh37]9p24.3-p23(271132-10112766) x~2-3) (Level mos 60%)

ppCVS_E: 2.8 Mb del, arr[GRCh37]9p24.3-p24.2(46587-2851026) x~1-2 and a 3.4 Mb dup (arr[GRCh37]9p24.2-p24.1(2871439-6272766) x~2-3). On 9q, 52 Mb del ((arr[GRCh37]9q21.129q33.2(72291978-124650611)x ~1-2) and terminal higher mosaic level of 0.6 Mb del arr[GRCh37]9q34.3(139999888-139403102 x ~1-2)). Mosaic level in sample E cannot be validly estimated due to maternal cell contamination.

2B:

Results from chromosome 1p of Case 13 are shown.

CVS: 2.3 Mb dup (aCGH: arr[GRCh37]1p36.33p36.32(564424-2842457)x~2-3 ; SNP-array: arr[GRCh37]1p36.33p36.32(752566-2817421)x~2-3) (Level mos 40-50/50-55%)

ppCVS_A : (MCC): 7.6 Mb mosaic deletion (MCC<15%) was detected (arr[GRCh37]1p36.33-p36.23(752566-8304607)x~1-2)

ppCVS_B : LOH of 31 Mb (arr[GRCh37]1p36.33-p35.2(752566-31713684)x2 hmz) (Level mos na) and a 1.8 Mb non-mosaic dup with LOH in the middle of the dup (arr[GRCh37]1p35.2-p35.1(31719450-33515210)x3)

ppCVS_C: LOH of 1.9 Mb (arr[GRCh37]1p36.33-p36.32(753541-1146459)x2 mos hmz) (Level mos na but lower than in sample D)

ppCVS_D: LOH of 1.9 Mb (arr[GRCh37]1p36.33-p36.32(753541-1146459)x2 mos hmz) ppCVS_E: 2.3 Mb dup (arr[GRCh37]1p36.33p36.32(1113121-2883858)x~2-3) (Level mos 50-55%).

2C:

Results from chromosome 20 of Case 11 are shown.

CVS, ppCVS_A,B,D,E: normal

ppCVS_C: 6.9 Mb dup (arr[GRCh37]20p13-p12.3(63,244-6,970,514) x~2-3).

2D:

Results from chromosome 5, 6 and 8 from Case 9 are shown.

CVS: Mosaicism for Trisomy 7 (data not shown)

ppCVS_D: 20 Mb dup on 5q (arr[GRCh37]5q34-q35.3(160069545-180705539)x~2-3), 7.2 Mb del on 6p (arr[GRCh37]6p25.3-p24.3(204909-7374207)x~1-2) and 762 Kb dup on 8q (arr[GRCh37]8q23.3p24.3(115543245-116305599)x3). LOH on chromosome 8 is not shown because all samples from case 9 showed LOH on random chromosomes due to consanguineous parents (8.8% consanguinity).











Abbreviations: CVS, chorionic villus sampling; dup, duplication; del, deletion; Level mos, level of mosaicism (frequency of abnormal cell line)






Figure 3. SNP array plots of Case 11 and Case 13 showing related concordant results between chorionic villus sample and postpartum chorionic villus samples at sites A-E.





Case 11: The six plots show the different aberrations (deletions and duplications) on chromosome 9 from the different samples.




Case 13: The six plots show the different aberrations (deletions, duplication and loss of heterozygosity) on chromosome 1p from the different samples. The duplication on CVS and ppCVS_E is exactly the same.



Abbreviations: CVS, chorionic villus sample; ppCVS, postpartum chorionic villus sample; MCC, maternal cell contamination.


<div>  <ul style="list-style-type: none">  Normal karyotype  Mosaic result (full concordance to CVS)  Non-mosaic abnormal result (full concordance to abnormal cell line in CVS)  Mosaic result (related concordance to CVS)  Non-mosaic abnormal result (related concordance to CVS)  Mosaic result (discordance to CVS – mosaicism including a different chromosome than the CVS result) </div>				
Given Case number	CVS aCGH - Karyotype (arr [GRCh37])	ppCVSs	Amniocytes – aCGH - Karyotype (GRCh37)	Postnatal Genetic analyses
1	(21)x2~3 20-30% T21			Buccal swab: T21 100% T21
2	(13)x2~3 10-20% T13	 <p>ppCVS_D: 70-75%</p>	(1-22,X)x2	na
3	(13)x2~3 15-25% T13		(1-22)x2, (X,Y)x1	na

4	(X)x1~2		na	Postnatal blood: mos 45X[1]/46,XX[9]. ish mos Xcen(DXZ1x1)[8]/ishX cen(DZX1x2)[42]
	80-90% Monosomy X	ppCVS_A: 85-90% ppCVS_B: 90-95% ppCVS_C-D:>95%		15%
5	(X)x1~2		(1-22,X)x2	na
	50% Monosomy X	ppCVS_B: 85-90%		
6	(7)x2~3		(1-22,X)x2	na
	55-65% T7	Level of mosaicism not possible due to MCC		-
7	(3)x2~3, (7)x2~3, (15)x2~3		(1-22)x2, (X,Y)x1	na
	<10% T3+T7+T15			-
8	(11)x2~3		(1-22)x2, (X,Y)x1	na
	<10% T11	ppCVS B and E: Failed (Formalin fixed)		-

9	<p>(7)x2~3</p>  <p>(1-22,X)x2</p> <p>na</p> <p>10-15% T7</p> <p>See Figure 2†</p>
10	<p>(7)x2~3</p>  <p>(1-22)x2, (X,Y)x1</p> <p>Pericardium: (1-22)x2, (X,Y)x1 by aCGH</p> <p>55-65% T7</p> <p>ppCVS_C: 65-70% ppCVS_A-B and d-E: Failed (Formalin fixed)</p>
11	<p>9p24.1p23 (8065133- 13415908) x2~3 dn†</p>  <p>(1-22)x2, (X,Y)x1</p> <p>na</p> <p>55-60% 9p24 dup (5.3 Mb)</p> <p>See Figure 2 and 3 ppCVS_C: one sample but two categories of results</p>
12	<p>(18p)x2~4</p>  <p>(1-22)x2, (X,Y)x1</p> <p>na</p> <p>25-30% T18p or 10-15% Tetrasomy 18p</p>

13	<p>1p36.33 p36.32 (564424-2842457) x2~3</p> <p>40-50% 1p36 dup (2.2 Mb)</p> <p>See Figure 2 and 3</p>		<p>(1-22)x2, (X,Y)x1</p> <p>na</p>
14	<p>7q11.21 (62833583-64767333) x2~3</p> <p>50% 7q11 dup (1.9 Mb)</p> <p>65-70% in all ppCVSs</p>		<p>na</p> <p>-</p>
15	<p>8q13.2q24.3 (69836784-145129457) x2~3</p> <p>20-30% 8q13 dup (75 Mb)</p>		<p>(1-22,X)x2</p>
<p>All abnormal ppCVS results can be found in Supplementary Figure S2. Results from repeated CVS analyses by SNP-array have not been included as these were concordant to aCGH results (max +/-20% difference in level of mosaicism); except two cases (case 8 and 9) where SNP-array did not confirm the prenatally detected low-level mosaicism by aCGH. This may reflect differences in sensitivity for detection of mosaic abnormalities of the two methods.</p> <p>†Regions with loss of heterozygosity on many chromosomes due to consanguinity (not on chr. 7)</p> <p>‡Parental array karyotypes were normal</p> <p>Abbreviations: CVS, chorionic villus sample; dup, duplication; MCC, maternal cell contamination; ppCVS, postpartum CVS</p>			





M

